VSTM

Verastem Inc

Add to Watchlist

Advanced Chart

8.135

-0.085(-1.034%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.290

Open

8.240

VWAP

8.17

Vol

605.42K

Mkt Cap

505.90M

Low

8.030

Amount

4.94M

EV/EBITDA(TTM)

Total Shares

25.33M

425.25M

EV/OCF(TTM)

P/S(TTM)

201.34

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

9 Analyst Rating

Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.25 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.135

Low

12.00

Averages

15.25

High

20.00

Current: 8.135

Low

12.00

Averages

15.25

High

20.00

Mizuho

Outperform

downgrade

$16 -> $14

2025-08-15

New

Reason

Mizuho

Price Target

$16 -> $14

2025-08-15

New

downgrade

Outperform

Reason

Mizuho lowered the firm's price target on Verastem to $14 from $16 primarily due to dilution from an April financing, while keeping an Outperform rating on the shares. The firm notes the company reported Q2 results last week, where key takeaways, in its view, were a revenue beat for recently launched Avmapki Fakzynja Co-pack/AFC; already, reimbursement for AFC use off-label in patients who are KRAS-wild-type; an October review for AFC's potential inclusion in NCCN guidelines; and all other pipeline programs remaining on track.

RBC Capital

Outperform

NULL

downgrade

$16 -> $12

2025-06-25

Reason

RBC Capital

Price Target

$16 -> $12

2025-06-25

downgrade

Outperform

NULL

Reason

RBC Capital lowered the firm's price target on Verastem to $12 from $16 and keeps an Outperform rating on the shares. The firm is updating its model after the approval of Av-Fak, ASCO data for Av-Fak in PDAC, and data from partnered G12D, the analyst tells investors in a research note. RBC adds that it sees significant upside in the pipeline, with potential for label expansions into PDAC or NSCLC.

H.C. Wainwright

Sean Lee

Buy

upgrade

$10 -> $14

2025-05-09

Reason

H.C. Wainwright

Sean Lee

Price Target

$10 -> $14

2025-05-09

upgrade

Buy

Reason

H.C. Wainwright analyst Sean Lee raised the firm's price target on Verastem to $14 from $10 and keeps a Buy rating on the shares after the company's avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.

RBC Capital

Gregory Renza

Outperform

maintain

$14 -> $16

2025-05-09

Reason

RBC Capital

Gregory Renza

Price Target

$14 -> $16

2025-05-09

maintain

Outperform

Reason

RBC Capital analyst Gregory Renza raised the firm's price target on Verastem to $16 from $14 and keeps an Outperform rating on the shares. The approval of Avmapki Fakzynja Co-Pack has transformed Verastem into a commercial-stage company with the first FDA-approved drug in LGSOC, low-grade serous ovarian cancer, and the launch blueprint with key strategic imperatives and a pricing model are well-thought-out and supported by reasonable analogs, the analyst tells investors in a research note.

Jefferies

Kelly Shi

Buy

maintain

$15 -> $19

2025-05-08

Reason

Jefferies

Kelly Shi

Price Target

$15 -> $19

2025-05-08

maintain

Buy

Reason

Jefferies analyst Kelly Shi raised the firm's price target on Verastem to $19 from $15 and keeps a Buy rating on the shares after the company received FDA approval for the avutometinib plus defactinib combo more than a month ahead of the PDUFA deadline of June 30. With the approval, the combination becomes the first approved therapy in the rare ovarian cancer of recurrent KRAS mutant LGSOC, the analyst noted. Physician feedback suggests "strong adoption enthusiasm" and the firm sees a $402M U.S. opportunity in KRAS mutant low-grade serous ovarian cancer alone, the analyst tells investors.

Jefferies

Kelly Shi

Strong Buy

Initiates

$15

2025-04-10

Reason

Jefferies

Kelly Shi

Price Target

$15

2025-04-10

Initiates

Strong Buy

Reason

Jefferies analyst Kelly Shi initiated coverage of Verastem with a Buy rating and $15 price target. The company has an FDA action date on June 30 for low-grade serous ovarian cancer, a rare ovarian cancer with no approved therapies, the analyst tells investors in a research note. The firm's key opinion leader feedback suggests "strong adoption enthusiasm" not only in the potential on-label KRASm population but also the rest due to the clinical profile and unmet need.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Verastem Inc (VSTM.O) is -3.46, compared to its 5-year average forward P/E of -5.26. For a more detailed relative valuation and DCF analysis to assess Verastem Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.26

Current PE

-3.46

Overvalued PE

2.22

Undervalued PE

-12.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.42

Undervalued EV/EBITDA

-0.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

655.87

Current PS

9.62

Overvalued PS

2435.64

Undervalued PS

-1123.90

Financials

Annual

Quarterly

FY2025Q2

YoY :

-78.63%

2.14M

Total Revenue

FY2025Q2

YoY :

+139.45%

-43.76M

Operating Profit

FY2025Q2

YoY :

+214.12%

-25.93M

Net Income after Tax

FY2025Q2

YoY :

+25.81%

-0.39

EPS - Diluted

FY2025Q2

YoY :

+18.44%

-32.66M

Free Cash Flow

FY2025Q2

YoY :

-20.87%

79.13

Gross Profit Margin - %

FY2025Q2

YoY :

+450.65%

-5.63K

FCF Margin - %

FY2025Q2

YoY :

+1369.92%

-1.21K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

127.2K

USD

3-6

Months

582.0K

USD

6-9

Months

58.1K

USD

0-12

Months

8.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

7.7K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1120.13% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

643.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.8M

Volume

Months

6-9

397.5K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

127.2K

USD

3-6

Months

582.0K

USD

6-9

Months

58.1K

USD

0-12

Months

8.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

7.7K

USD

Months

VSTM News & Events

Events Timeline

2025-08-13 (ET)

2025-08-13

16:35:44

Verastem's VS-7375 shows efficacy in lung cancer

2025-08-07 (ET)

2025-08-07

17:10:22

Verastem reports Q2 EPS (39c) vs. (31c) last year

2025-07-11 (ET)

2025-07-11

16:26:53

Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology

News

9.0

08-13Newsfilter

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

9.5

08-10Yahoo Finance

Verastem Second Quarter 2025 Earnings: Beats Expectations

9.5

08-08SeekingAlpha

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline